News
GLP-1 RA use increases risk for nonarteritic anterior ischemic optic neuropathy compared with other second-line antidiabetic medications.
(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback